Satellos Bioscience (MSCL) Price & Analysis

Compare

25 Followers

MSCL Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$0.38 - C$1.32

Previous CloseN/A

Volume29.01K

Average Volume (3M)149.51K

Market Cap

$96.63M

Enterprise ValueC$67.78M

Total Cash (Recent Filing)C$1.92M

Total Debt (Recent Filing)C$0.00

Price to Earnings (P/E)―

Beta0.77

Next Earnings

Jun 03, 2025

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding153,375,400

10 Day Avg. Volume96,406

30 Day Avg. Volume149,511

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$1.23

Price Target Upside95.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

---

Satellos Bioscience News

PremiumCompany Announcements

Satellos Bioscience to Present at Healthcare Investor Conference

4d ago

PremiumCompany Announcements

Satellos Bioscience to Engage with Investors at April Conferences

1M ago

PremiumRatings

Satellos Bioscience: Buy Rating Backed by Promising Clinical Progress and Robust Financial Position

1M ago

PremiumCompany Announcements

Satellos Bioscience Advances DMD Therapy with Promising Trial Results

1M ago

PremiumPre-Earnings

MSCLF Upcoming Earnings Report: What to Expect?

1M ago

PremiumCompany Announcements

Satellos Bioscience Reports Positive Initial Data from Phase 1 Trial of SAT-3247

2M ago

PremiumCompany Announcements

Satellos Bioscience to Present Phase 1 Data for SAT-3247 at MDA Conference

2M ago

PremiumCompany Announcements

Satellos Completes Phase 1 Enrollment for DMD Drug Trial

3M ago

See All TSE:MSCL News

---

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe company has made significant progress, well positioning itself for the next value inflection point.

Safety And TolerancePhase 1a data demonstrated that SAT-3247 was safe and well-tolerated across multiple dosage levels.

Bears Say

Financial PerformanceThe company reported no revenue, in line with the consensus estimate, and a net loss.

---

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

23.57% Insiders

0.76%

Mutual Funds

― Other Institutional Investors

75.67% Public Companies and

Individual Investors

Detailed Ownership Overview >

MSCL FAQ

What was Satellos Bioscience’s price range in the past 12 months?

Satellos Bioscience lowest stock price was C$0.38 and its highest was C$1.32 in the past 12 months.

What is Satellos Bioscience’s market cap?

Satellos Bioscience’s market cap is $96.63M.

When is Satellos Bioscience’s upcoming earnings report date?

Satellos Bioscience’s upcoming earnings report date is Jun 03, 2025 which is in 31 days.

How were Satellos Bioscience’s earnings last quarter?

Satellos Bioscience released its earnings results on Mar 26, 2025. The company reported -C$0.06 earnings per share for the quarter, missing the consensus estimate of -C$0.041 by -C$0.019.

Is Satellos Bioscience overvalued?

According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Satellos Bioscience pay dividends?

Satellos Bioscience does not currently pay dividends.

What is Satellos Bioscience’s EPS estimate?

Satellos Bioscience’s EPS estimate is -0.05.

How many shares outstanding does Satellos Bioscience have?

Satellos Bioscience has 153,375,400 shares outstanding.

What happened to Satellos Bioscience’s price movement after its last earnings report?

Satellos Bioscience reported an EPS of -C$0.06 in its last earnings report, missing expectations of -C$0.041. Following the earnings report the stock price went up 2.564%.

Which hedge fund is a major shareholder of Satellos Bioscience?

Currently, no hedge funds are holding shares in TSE:MSCL

---

Satellos Bioscience Stock Smart Score

Neutral

Fundamentals

Return on Equity

-52.63%

Trailing 12-Months

Asset Growth

51.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Satellos Bioscience

Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

---

MSCL Stock 12 Month Forecast

Average Price Target

C$1.23

▲(95.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"C$2","-1":"-C$1","-0.25":"-C$0.25","0.5":"C$0.5","1.25":"C$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.251162089791875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$1.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.2312579065,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$1.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.2011156062002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$1.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,0.9085509299839903,0.9371018599679808,0.9656527899519711,0.9942037199359615,1.022754649919952,1.0513055799039424,1.0798565098879327,1.108407439871923,1.1369583698559134,1.1655092998399037,1.194060229823894,1.2226111598078846,{"y":1.251162089791875,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,0.9070198389615385,0.934039677923077,0.9610595168846154,0.9880793558461538,1.0150991948076924,1.0421190337692308,1.0691388727307691,1.0961587116923077,1.123178550653846,1.1501983896153847,1.177218228576923,1.2042380675384616,{"y":1.2312579065,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,0.9047012004769385,0.9294024009538769,0.9541036014308154,0.9788048019077539,1.0035060023846922,1.0282072028616307,1.0529084033385692,1.0776096038155076,1.102310804292446,1.1270120047693846,1.151713205246323,1.1764144057232615,{"y":1.2011156062002,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.475,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.45,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.53,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.69,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.5,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.5,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >